雷替曲塞联合奥沙利铂二线治疗晚期结直肠癌的临床分析  

Clinical Analysis of Raltitrexed Combined With Oxaliplatin in the Second-line Treatment of Advanced Colorectal Cancer

作　　者：钱辉 

机构地区：[1]江苏省宜兴市肿瘤医院肿瘤科,江苏宜兴214200

出　　处：《中国继续医学教育》2017年第24期163-165,共3页China Continuing Medical Education

摘　　要：目的探讨晚期结直肠癌治疗中联用雷替曲塞、奥沙利铂与联用雷替曲塞、伊利替康展开二线治疗的效果。方法将50例晚期结直肠癌患者为两组,25例雷替曲塞、奥沙利铂展开治疗为A组,25例联用雷替曲塞、伊利替康为B组,对比两组效果。结果 A组RR是52.00%,B组为48.00%,对比差异无统计学意义,P>0.05;两组不良反应主要是白细胞下降、血小板降低、神经毒性、恶心呕吐、腹泻、肝功能损坏,组间对比差异无统计学意义,P>0.05。结论对于晚期结直肠癌的治疗,联用雷替曲塞与奥沙利铂或伊利替康疗效相当,且毒副作用均可耐受。Objective To investigate the efficacy of combined use of pemetrexed, oxaliplatin, and combination of pemetrexed and irinotecan in the treatment of advanced colorectal cancer. Methods 50 cases of advanced colorectal cancer patients were divided into two groups, 25 cases were treated with pemetrexed and oxaliplatin as A group, 25 cases were treated with pemetrexed and irinotecan as B group, and the efect of the two groups was compared. Results A group RR was 52%, B group was 48%, compared to no signifcant diference, P 〉 0.05; The two groups of adverse reactions were mainly white blood cell decline, thrombocytopenia, neurotoxicity, nausea, vomiting, diarrhea, liver function damage, the diference between groups was not statistically significant, P 〉 0.05. Conclusion For the treatment of advanced colorectal cancer, the efcacy of combination with oxaliplatin or irinotecan is similar, and the toxicity and side efects can be tolerated.

关 键 词：晚期结直肠癌 雷替曲塞 奥沙利铂 伊利替康 

分 类 号：R735[医药卫生—肿瘤]